Phase 2 Cutaneous T Cell Lymphoma Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 2
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Cutaneous T Cell LymphomaFungoides Mycosis Sezary Syndrome
University of Michigan Rogel Cancer Center23 enrolled1 locationNCT05956041
Recruiting
Phase 2
Photopheresis in Early-stage Mycosis Fungoides
Mycosis FungoidesCutaneous T Cell Lymphoma
Columbia University74 enrolled1 locationNCT05680558
Recruiting
Phase 2
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
T-cell LymphomaT-cell Prolymphocytic LeukemiaLymphoma, T-Cell+5 more
Jonathan Brammer44 enrolled1 locationNCT07356245
Recruiting
Phase 2
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
Cutaneous T Cell Lymphoma
M.D. Anderson Cancer Center20 enrolled1 locationNCT06698822
Recruiting
Phase 1Phase 2
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+8 more
Ossium Health, Inc.12 enrolled9 locationsNCT05589896
Recruiting
Phase 2
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Lymphoma, T-CellT-LGL LeukemiaNK-LGL Leukemia+7 more
Institute of Hematology & Blood Diseases Hospital, China48 enrolled2 locationsNCT06716658
Terminated
Phase 2
Trial of KPT-330 in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T cell Lymphoma (CTCL)
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Relapsed or Refractory Cutaneous T cell Lymphoma (CTCL)
Karyopharm Therapeutics Inc.30 enrolled4 locationsACTRN12614001328662